Chiesi Deal History & Licensing Activity
Chiesi is a large pharma headquartered in Italy. Over the past three years, Chiesi has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals).
Deals (12mo)
1
Active Trials
10
Top Modality
Small Molecules
Focus Area
Rare Disease
Chiesi Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chiesi in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Sebetralstat | Chiesi Group | Small Molecules | Phase 3 | acquisition | Jun 11, 2026 |
| Ekterly | KalVista | Small Molecules | Unknown | acquisition | Apr 15, 2026 |
Chiesi Pipeline Focus
Therapeutic areas and modalities where Chiesi is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Chiesi Strategic Signals
Key indicators of Chiesi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Chiesi's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Chiesi Licensing & Deal Activity
Chiesi is a large pharma company based in Italy that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Chiesi ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chiesi include Rare Disease (4 deals and trials), and Infectious Disease (1 deal and trial). In terms of modality, Chiesi has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chiesi and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Chiesi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.